Session » (0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

Date: Sunday, November 12, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 0487

A Comparative Study of Serositis Between Inpatients with Psoriatic Arthritis and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0500

Analysis of the Probability of Retention of Golimumab as a Two-phase Exponential Decay Curve in Rheumatoid Arthritis or Spondyloarthropathies to Identify Patients with Higher Probability of Long-term Retention

9:00AM-11:00AM: Abstract Number: 0491

Arthralgia with Risk of Progression to Psoriatic Arthritis in a Large Cohort of Patients: Role of Ultrasound

9:00AM-11:00AM: Abstract Number: 0509

Assessment of Direct and Indirect Impact on Pain and Fatigue Outcomes in a Phase 2 Clinical Trial of Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Active PsA: A Mediation Analysis

9:00AM-11:00AM: Abstract Number: 0508

Assessment of Pain Outcomes in a Phase 2 Trial of a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients with Active PsA

9:00AM-11:00AM: Abstract Number: 0493

Axial Disease Activity in Psoriatic Arthritis Is Higher in Patients with Carotid Plaque

9:00AM-11:00AM: Abstract Number: 0492

Axial Spondyloarthritis in Patients with Late-Onset Chronic Low Back Pain (Older Than 45 Years). Axial Spa or Psoriatic Disease with Axial Involvement?

9:00AM-11:00AM: Abstract Number: 0498

Biological Therapies for Psoriasis and Psoriatic Arthritis- effects on Future Risk Development of Major Adverse Cardiovascular Events (MACE)

9:00AM-11:00AM: Abstract Number: 0504

Burden of Disease of Psoriatic Arthritis in Latin America: A Systemic Review of Literature

9:00AM-11:00AM: Abstract Number: 0502

Developing Electronic Health Record Algorithms to Accurately Identify Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 0499

Durability of Response Among Patients with Psoriatic Arthritis (PsA) Using Biological or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/Spondyloarthritis Registry

9:00AM-11:00AM: Abstract Number: 0497

Effects and Tolerability of Low to Moderate Biomechanical Stress During Leisure Sport Activity in Patients with Psoriasis and Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0505

Factors Associated with Minimal Disease Activity in Psoriatic Arthritis: Insights from a Registry-Based Study

9:00AM-11:00AM: Abstract Number: 0488

Factors Associated with Work Productivity Among Individuals with Psoriatic Arthritis (PsA) and Psoriasis (PsO): The Role of Patient Reported Outcomes and Disease Severity

9:00AM-11:00AM: Abstract Number: 0484

Higher Levels of High-sensitivity CRP Are Associated with Future Risk of Developing Psoriatic Arthritis Among Patients with Psoriasis: A Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 0496

Higher Values of Atherogenic Index of Plasma Are Correlated with Increased Cardiovascular Risk in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0486

Identifying Serum Metabolomic Markers Associated with Psoriasis Skin Disease Activity

9:00AM-11:00AM: Abstract Number: 0494

Levels of Atherosclerotic Index of Plasma and Triglyceride Glucose Index in Patients with Psoriatic Arthritis and Carotid Plaque

9:00AM-11:00AM: Abstract Number: 0501

Multicentre Study of Uveitis in Spondyloarthritis: Prevalence, Characteristics, and Prognosis

9:00AM-11:00AM: Abstract Number: 0506

Patient and Physician Global Assessment of Psoriatic Arthritis Disease Activity: High Concordance in an ArLAR Multinational Study

9:00AM-11:00AM: Abstract Number: 0489

Prediction of Low Disease Activity in Patients with Psoriatic Arthritis Treated with Secukinumab in Real World – Data from a German Observational Study

9:00AM-11:00AM: Abstract Number: 0495

Prevalence of Undiagnosed Inflammatory Bowel Disease in Patients with Spondyloarthritis: EISER Study

9:00AM-11:00AM: Abstract Number: 0490

Racial/Ethnic Differences in Psoriatic Arthritis Patient Responses Regarding Disease Burden, Treatment, and Communication with Care Team

9:00AM-11:00AM: Abstract Number: 0485

Sex and Treatment-associated Outcomes in Patients with Active Psoriatic Arthritis Treated with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial

9:00AM-11:00AM: Abstract Number: 0503

Spinal Inflammation a Dominant Pathology in Psoriatic Arthritis: Characterization and Quantification by In-Vivo 18F-FDG Total-Body PET/CT Imaging

9:00AM-11:00AM: Abstract Number: 0483

The Influence of “Fibromyalgia-ness” on Treatment Response Amongst Patients with Psoriatic Arthritis (PsA). Results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR‐PsA)

9:00AM-11:00AM: Abstract Number: 0507

The Use of PSAID-12 in Remote Monitoring Correlates with In-person Clinical Examination Findings in Psoratic Arthritis

« View all sessions from this meeting